Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope

About PBD Biotech

PBD Biotech is developing Actiphage TB to achieve the goals of the WHO End TB strategy.

Loading...
  • Co-founded in 2014 as academic spin-out
  • First clinical study initiated 2017
  • Jane Theaker, Chief Executive Officer since December, 2021
  • Actiphage patents published:
    • 2015 Mycobacteria Detection using bacteriophages
    • 2020 Methods relating to Tuberculosis (the transition from incipient to active infection in LTBI patients)
  • Clinical research
    • 2020 Actiphage Proof-of-Concept (POC) Leicester 1, published CID
    • 2022 Actiphage POC Leicester 2, presented ECCMID 2022

Actiphage is industry recognised:

2020 Actiphage proof-of-Concept Leicester 1, published CID2022

Actiphage proof-of-concept Leicester 2, presented ECCMID 2022

Related content

Loading...
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test
October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic with potential to revolutionise management of TB.
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test
October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic...

Innovation is a key differentiator, PBD Biotech CEO to say at Invest Midlands
January 17, 2022
Innovation directed at an unmet market need can stimulate economic development if the value creation is kept within the local economy. The recent pandemic has shown the huge value of diagnostics and tuberculosis (TB), for which there are currently few...

Innovation is a key differentiator, PBD Biotech CEO to say at Invest Midlands
January 17, 2022
Innovation directed at an unmet market need can stimulate economic development if the value creation is kept within the local...
Jane Theaker, CEO, PBD Biotech (c) Chelsea Shoesmith Photography - square

Jane Theaker appointed as new CEO as PBD Biotech gears up for next phase of development
December 10, 2021
PBD Biotech, developers of a phage-based diagnostic for tuberculosis, is moving to the next stage of its development. It is appointing Jane Theaker, of precision medicine company Kinomica, as the new CEO and bringing Commercial Director, Jonnie Yewdall, into a...
Jane Theaker, CEO, PBD Biotech (c) Chelsea Shoesmith Photography - square

Jane Theaker appointed as new CEO as PBD Biotech gears up for next phase of development
December 10, 2021
PBD Biotech, developers of a phage-based diagnostic for tuberculosis, is moving to the next stage of its development. It is...
1 2

developers of phage-based diagnostics

Contact Us
BIVDA member 2023

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house